ArticleBioactive materials2026
Charge Au@Pt NPs combined with 3D STS-Net for adaptive and sensitized radiotherapy of hepatocellular carcinoma: Synergistic enhancement of therapeutic gain across physical and biological dimensions.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic gain ratio (TGR) of radiotherapy for hepatocellular carcinoma (HCC) remains limited by two major barriers: insufficient precision in adaptive radiotherapy (ART) on the physical dimension and the lack of effective radiosensitization on the biological dimension. Although advances have been made separately in accurate dose delivery and tumor-sensitizing strategies, no approach has yet integrated both dimensions to achieve a coordinated improvement in TGR, representing a critical gap in current practice. In this study, we propose an integrated physical-biological strategy that combines nanomaterials with artificial intelligence (AI). We first constructed charge-engineered gold-platinum nanoparticles that respond to the acidic tumor microenvironment and enable prolonged, high-contrast computed tomography imaging of HCC. These enhanced images were then used to develop the first Transformer-convolutional neural network hybrid model (3D STS-Net) tailored for this scenario, enabling high-accuracy three-dimensional segmentation of small HCC for image-guided adaptive radiotherapy. In parallel, we systematically evaluated the nanoparticles' radiosensitizing effects in vitro and in vivo. The nanoparticles provided stable imaging enhancement for up to 120 h and markedly improved tumor-liver contrast. The 3D STS-Net achieved high segmentation accuracy, supporting more precise contouring for HCC ART. Moreover, the nanoparticles significantly increased radiation-induced reactive oxygen species and enhanced tumor control in animal models. Together, these findings demonstrate that the proposed strategy simultaneously strengthens radiotherapy performance in both physical and biological dimensions, leading to a coordinated improvement in TGR. This integrated "nanomaterial-AI" framework offers a systematic and generalizable approach for enhancing radiotherapy effectiveness in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.